OpGen (OPGN) Reaches New 1-Year Low at $1.02

OpGen Inc (NASDAQ:OPGN) shares hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $1.02 and last traded at $1.05, with a volume of 623 shares. The stock had previously closed at $1.09.

Several research analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of OpGen from a “buy” rating to a “hold” rating in a report on Wednesday, November 7th. HC Wainwright set a $6.00 price target on shares of OpGen and gave the stock a “buy” rating in a report on Wednesday, November 7th.

The firm has a market cap of $9.38 million, a price-to-earnings ratio of -0.11 and a beta of 1.92. The company has a quick ratio of 1.43, a current ratio of 1.56 and a debt-to-equity ratio of 0.28.

OpGen (NASDAQ:OPGN) last posted its quarterly earnings data on Tuesday, November 13th. The medical research company reported ($0.53) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.02. The business had revenue of $0.55 million during the quarter, compared to the consensus estimate of $0.56 million. OpGen had a negative return on equity of 238.35% and a negative net margin of 395.63%. Equities research analysts forecast that OpGen Inc will post -2.19 EPS for the current fiscal year.

A hedge fund recently bought a new stake in OpGen stock. Acadian Asset Management LLC acquired a new stake in OpGen Inc (NASDAQ:OPGN) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 58,906 shares of the medical research company’s stock, valued at approximately $105,000. Acadian Asset Management LLC owned 0.99% of OpGen as of its most recent SEC filing. 4.08% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “OpGen (OPGN) Reaches New 1-Year Low at $1.02” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/12/07/opgen-opgn-reaches-new-1-year-low-at-1-02.html.


OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.

Recommended Story: Fiduciary

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply